Bio

Winton Gibbons

My background merges industry, management consulting, and financial services, predominantly for innovative clinical diagnostic, life science, and therapeutic companies. These have been based on biotechnology, nanotechnology, and microfluidics, as well as novel biomarkers. This experience enables me to contribute highly as an independent consultant.

EXPERIENCE SUMMARY

Independent Consultant

Diagnostics, Life Science, and Biotechnology Consulting for Investors, CEOs, and Functional | Department Heads

Senior Vice President – Corporate Development

Agena Biosciences (2015 – 2016)

Genetic Testing (Mass Spectrometry)

CEO & President

Siloam Biosciences (2014 – 2015)

Clinical Diagnostics (Microfluidics)

Senior Vice President – Business Development & Research

Nanosphere ( 2007 – 2013)

Clinical Diagnostics (Nanotechnology)

Senior Vice President – Strategic Marketing & Product Management

Biosite (Alere) (2005 – 2007)

Clinical Diagnostics (Biotechnology)

Principal and Group Head – Healthcare Equity Research

William Blair & Company (1997 – 2005)

Investment Banking

Vice President – Strategy & Business Development

Boehringer Mannheim (Roche) (1994 – 1997)

Diagnostics and Pharmaceuticals

Director – Management Services

Merck & Co. (1993 – 1994)

Pharmaceuticals                                                                                                                             

Manager

McKinsey & Company (1989 – 1993)

Management Consulting

EDUCATION

University of Chicago Booth School of Business

MBA Finance

Duke University

BS Chemistry

ADDITIONAL PROFESSIONAL SUMMARY

Boards

Investor Board for the Innovation and New Ventures Office of Northwestern University (technology transfer)

Advisory Board and Guest Lecturer for the Kellogg School of Management – Center for Biotechnology – 1998 to 2010

Mentor

Chicago Innovation Mentors program – a consortium of University of Chicago, Northwestern University and University of Illinois. Mentor team leader for a urological in-vivo diagnostic.

Other

Patent filings – Four published applications, numerous other disclosures and filings

One thousand financial reports and commentaries

Quoted by Biocentury, Bloomberg and Bloomberg TV, Boston Herald, CBS Market Watch, Chicago Tribune, CNBC TV, Dow Jones, Forbes, In Vivo, Investor’s Business Daily, MSNBC TV, Nature, New York Times, PBS, Reuters, San Francisco Chronicle, SmartMoney.com, TheStreet.com, USA Today, Wall Street Journal, and Washington Post.